SOURCE: Goldman Small Cap Research, Inc.

June 03, 2013 09:25 ET

Nuvilex Could Help Shape the Future of Medical Marijuana

BALTIMORE, MD--(Marketwired - Jun 3, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, believes that Nuvilex Inc. (OTCQB: NVLX) stands ready to engage in comprehensive research and development that could eventually result in landmark therapeutic success. The Company is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients. 

The Company is poised to meld its highly regarded live cell-encapsulation technology to treat certain cancers in clinical trials and other tests, with the use of cannabinoids which have demonstrated an ability to act as anticancer agents in various studies. Clearly, this live-cell encapsulation technology and cannabinoid combination is both proprietary and unique relative to anything the market has seen to date.

Unlike most firms engaged in research and development in the medical marijuana space, Nuvilex is not focused on pain management or nausea, etc. Since the basis of its platform live-cell encapsulation technology is to target the tumor, potentially inhibit progression, and treat it at its core, many cancer patients may monitor the Company's progress with earnest, especially those who claim a halting in tumor progression due to use of medical marijuana.

In addition, since there are likely few safety and toxicity issues with medical marijuana, the development time may be shortened. Once sufficient volumes of cells and product are procured the Company can engage in a series of proper lab tests which could theoretically lead directly to Phase II human trials. Given the success of its pancreatic cancer trials and the clamor for true comprehensive medical marijuana research and development in oncology, Nuvilex is likely to garner quite a following as a leader in the space which is fast gaining allies and proponents, as evidenced by the recent Barron's cover story on marijuana. 

A copy of this article as well as other articles and Nuvilex reports can be accessed by visiting

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit:

Contact Information